ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 145 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $400,703 | +12.5% | 75,462 | +101.9% | 0.00% | 0.0% |
Q2 2023 | $356,136 | -17.8% | 37,370 | -5.1% | 0.00% | 0.0% |
Q1 2023 | $433,081 | -26.2% | 39,371 | -0.7% | 0.00% | -50.0% |
Q4 2022 | $586,894 | -27.0% | 39,655 | -5.8% | 0.00% | -33.3% |
Q3 2022 | $804,000 | +33.8% | 42,081 | +49.3% | 0.00% | +50.0% |
Q2 2022 | $601,000 | +23.4% | 28,192 | +11.4% | 0.00% | +100.0% |
Q1 2022 | $487,000 | -7.2% | 25,300 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $525,000 | -13.1% | 25,300 | 0.0% | 0.00% | 0.0% |
Q3 2021 | $604,000 | -12.5% | 25,300 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $690,000 | -5.7% | 25,300 | 0.0% | 0.00% | -50.0% |
Q1 2021 | $732,000 | +2.8% | 25,300 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $712,000 | +51.8% | 25,300 | +58.1% | 0.00% | +100.0% |
Q3 2020 | $469,000 | -3.1% | 16,000 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $484,000 | +1.5% | 16,000 | 0.0% | 0.00% | -50.0% |
Q1 2020 | $477,000 | – | 16,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Frazier Life Sciences Management, L.P. | 8,684,232 | $165,956,000 | 12.78% |
Bain Capital Life Sciences Investors, LLC | 3,000,000 | $57,330,000 | 6.84% |
Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,874,000 | 3.97% |
Logos Global Management LP | 1,525,000 | $29,143,000 | 3.58% |
1492 Capital Management LLC | 178,320 | $3,408,000 | 2.45% |
Cormorant Asset Management, LP | 1,000,000 | $19,110,000 | 1.34% |
MPM BioImpact LLC | 257,185 | $4,915,000 | 1.16% |
Orbimed Advisors | 2,800,000 | $53,508,000 | 0.99% |
SECTORAL ASSET MANAGEMENT INC | 220,985 | $4,223,000 | 0.83% |
Rubric Capital Management LP | 472,047 | $9,021,000 | 0.45% |